The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies

被引：19
|
作者：
Skarbnik, Alan P. [1 ]
Faderl, Stefan [2 ]
机构：
[1] Hackensack Univ, Med Ctr, Div Lymphoma, John Theurer Canc Ctr,Blood & Marrow Transplantat, 92 Second St, Hackensack, NJ 07624 USA
[2] Hackensack Univ, Med Ctr, Div Leukemia, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
THERAPEUTIC ADVANCES IN HEMATOLOGY | 2017年 / 8卷 / 03期
关键词：
chemoimmunotherapy; CLL; FCR; fludarabine; rituximab; PREVIOUSLY UNTREATED PATIENTS; LOW-DOSE FLUDARABINE; INITIAL THERAPY; OPEN-LABEL; AGENT; CHLORAMBUCIL; REGIMEN; FCR; CHEMOTHERAPY; VINCRISTINE;
D O I：
10.1177/2040620716681749
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chemoimmunotherapy (CIT) has become a cornerstone in the treatment of patients with chronic lymphocytic leukemia (CLL). The combination of fludarabine, cyclophosphamide and rituximab (FCR) has emerged as the standard of care for therapy of previously untreated patients with CLL who are younger than 65 years and have no significant comorbidities. In this article, we review the role of FCR in the current treatment paradigm for CLL.
引用
下载
收藏
页数：8
相关论文
共 50 条
  • [1] Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    Wierda, W
    O'Brien, S
    Wen, S
    Faderl, S
    Garcia-Manero, G
    Thomas, D
    Do, KA
    Cortes, J
    Koller, C
    Beran, M
    Ferrajoli, A
    Giles, F
    Lerner, S
    Albitar, M
    Kantarjian, H
    Keating, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4070 - 4078
  • [2] Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia
    Parikh, Sameer A.
    Keating, Michael
    O'Brien, Susan
    Ferrajoli, Alessandra
    Faderl, Stefan
    Koller, Charles
    Estrov, Zeev
    Lerner, Susan
    Wierda, William G.
    BLOOD, 2009, 114 (22) : 91 - 92
  • [3] Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
    Parikh, Sameer A.
    Keating, Michael J.
    O'Brien, Susan
    Wang, Xuemei
    Ferrajoli, Alessandra
    Faderl, Stefan
    Burger, Jan
    Koller, Charles
    Estrov, Zeev
    Badoux, Xavier
    Lerner, Susan
    Wierda, William G.
    BLOOD, 2011, 118 (08) : 2062 - 2068
  • [4] Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia
    Bosch, Francesc
    Abrisqueta, Pau
    Villamor, Neus
    Jose Terol, Maria
    Gonzalez-Barca, Eva
    Ferra, Christelle
    Gonzalez Diaz, Marcos
    Abella, Eugenia
    Delgado, Julio
    Carbonell, Felix
    Garcia Marco, Jose Antonio
    Escoda, Lourdes
    Ferrer, Secundino
    Monzo, Encarnacion
    Gonzalez, Yolanda
    Estany, Cristina
    Jarque, Isidro
    Salamero, Olga
    Muntanola, Ana
    Montserrat, Emili
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4578 - 4584
  • [5] Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
    Keating, MJ
    O'Brien, S
    Albitar, M
    Lerner, S
    Plunkett, W
    Giles, F
    Andreeff, M
    Cortes, J
    Faderl, S
    Thomas, D
    Koller, C
    Wierda, W
    Detry, MA
    Lynn, A
    Kantarjian, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4079 - 4088
  • [6] Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) Is a Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia
    Bosch, Francesc
    Abrisqueta, Pau
    Villamor, Neus
    Terol, Maria Jose
    Ribera, Josep-Maria
    Gonzalez-Barca, Eva
    Gonzalez, Marcos
    Abella, Eugenia
    Delgado, Julio
    Gonzalez, Yolanda
    Ferrer, Secundino
    Carbonell, Felix
    Escoda, Lourdes
    Jarque, Isidro
    Monzo, Encamacion
    Muntanola, Ana
    Salamero, Olga
    Montserrat, Emili
    BLOOD, 2008, 112 (11) : 730 - 730
  • [7] Long-Term Results of Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
    Badoux, Xavier
    Keating, Michael J.
    Ferrajoli, Alessandra
    Lerner, Susan
    Wang, Xuemei
    O'Brien, Susan
    Wierda, William G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (03): : E35 - E35
  • [8] PROLONGED CYTOPENIA RELATED TO FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Strati, P.
    Wierda, W.
    Burger, J.
    Ferrajoli, A.
    Lerner, S.
    Keating, M.
    O'Brien, S.
    HAEMATOLOGICA, 2013, 98 : 45 - 45
  • [9] Fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia: no country for old men?
    Terry J Hamblin
    Nature Reviews Clinical Oncology, 2009, 6 : 130 - 131
  • [10] Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia
    Robak, Tadeusz
    Lech-Maranda, Ewa
    Robak, Pawel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1529 - 1543
12345